Amgen’s Mvasi Biosimilar Overtakes Avastin In The US

California-Based Giant Enjoyed Biosimilars Sales Of $1.7bn Last Year

 
• By Dean Rudge
  
AMGEN_1174421407_1200.jpg
Amgen has just launched its fifth biosimilar in the US, a rival to rituximab. • Source: Amgen
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products